The new addition will also launch a single-use bioreactor for the 93,000-ft2 facility.
Rentschler Biopharma, a Germany-based contract development and manufacturing organization (CDMO), announced it is opening a center of excellence in Milford, MA, to expand its US footprint. The new addition will also launch a single-use bioreactor for the 93,000-ft2 facility, according to a Nov. 6, 2019 Rentschler press release.
The new XDR-500 bioreactor is equipped with a working volume of 100–500 L, downstream process capabilities of 2–8 g/L, and is part of the state-of-the-art GMP facility suite concept, according to the release. The system is set to be client-ready in mid-2020.
Additionally, the company is planning on adding a separate building to the site for large-scale and single-use manufacturing, and lab capacity for new modalities.
Dr. Jesús Zurdo, senior vice-president, Innovation and Venture Partnerships at Rentschler, will present the company’s clinical and commercial manufacturing capabilities at BIO-Europe from Nov. 11–13 in Hamburg, Germany.
Source: Rentschler Biopharma
Thermo Fisher Opens Advanced Therapies Collaboration Center in California
April 18th 2025The 6000-square-foot facility will provide cell therapy developers the support they need to transition to CGMP manufacturing, and an expanded footprint of the new center is expected to open in Philadelphia later in 2025.